In English | En español
Questions About Cancer? 1-800-4-CANCER

Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)

  • Last Modified: 09/04/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Changes to This Summary (09/04/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was comprehensively reviewed.

General Information About Osteosarcoma and Malignant Fibrous Histiocytoma (MFH) of Bone

Revised text to state that between 1975 and 2010, childhood cancer mortality decreased by more than 50%; for osteosarcoma, the 5-year survival rate increased over the same time from 40% to 76% in children younger than 15 years and from 56% to approximately 66% in adolescents aged 15 to 19 years (cited Smith et al. as reference 1).

Added Meyers et al. as reference 27.

Added text to state that increased body mass index at initial presentation is associated with worse overall survival (cited Altaf et al. as reference 56).

Revised Table 1 to include descriptions for all syndomes that predispose to osteosarcoma.

Localized Osteosarcoma and MFH of Bone

Revised text to state that patients with localized osteosarcoma undergoing surgery and chemotherapy have a 5-year overall survival (OS) of 62% to 65% (cited Smith et al. as reference 1).

Revised text to state that it is preferable that the biopsy be done by a surgeon skilled in the techniques of limb sparing; in these cases, the original biopsy incision placement is crucial. Also added text to state that inappropriate alignment of the biopsy or inadvertent contamination of soft tissues can render subsequent limb-preserving reconstructive surgery impossible.

Added text to state that the degree of necrosis observed in the primary tumor after an initial period of chemotherapy correlates with subsequent event-free survival and overall survival. Also added text about a large prospective randomized trial that was conducted by an international consortium to study survival for patients with varying degrees of necrosis (cited Bielack et al. as reference 34).

Added text to state that the Italian Sarcoma Group and the Scandinavian Sarcoma Group performed a clinical trial in patients with osteosarcoma who presented with clinically detectable metastatic disease. Consolidation with high-dose etoposide and carboplatin followed by autologous stem cell reconstitution did not appear to improve outcome and the investigators do not recommend this strategy for the treatment of osteosarcoma (cited Boye et al. as reference 35).

Osteosarcoma and MFH of Bone With Metastatic Disease at Diagnosis

Added Kempf-Bielack et al. as reference 2.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.